Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15219, USA.
J Biol Chem. 2013 Feb 22;288(8):5443-50. doi: 10.1074/jbc.R112.438382. Epub 2013 Jan 11.
The c-abl proto-oncogene encodes a unique protein-tyrosine kinase (Abl) distinct from c-Src, c-Fes, and other cytoplasmic tyrosine kinases. In normal cells, Abl plays prominent roles in cellular responses to genotoxic stress as well as in the regulation of the actin cytoskeleton. Abl is also well known in the context of Bcr-Abl, the oncogenic fusion protein characteristic of chronic myelogenous leukemia. Selective inhibitors of Bcr-Abl, of which imatinib is the prototype, have had a tremendous impact on clinical outcomes in chronic myelogenous leukemia and revolutionized the field of targeted cancer therapy. In this minireview, we focus on the structural organization and dynamics of Abl kinases and how these features influence inhibitor sensitivity.
c-abl 原癌基因编码一种独特的蛋白酪氨酸激酶(Abl),与 c-Src、c-Fes 和其他细胞质酪氨酸激酶不同。在正常细胞中,Abl 在细胞对遗传毒性应激的反应以及调节肌动蛋白细胞骨架方面发挥着重要作用。在 Bcr-Abl 中,Abl 也很有名,Bcr-Abl 是慢性髓性白血病的致癌融合蛋白。Bcr-Abl 的选择性抑制剂,其中伊马替尼是原型,对慢性髓性白血病的临床结果产生了巨大影响,并彻底改变了靶向癌症治疗领域。在这篇综述中,我们重点介绍 Abl 激酶的结构组织和动力学,以及这些特征如何影响抑制剂的敏感性。